Guo-He Lin's research while affiliated with First Affiliated Hospital of China Medical University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (34)
Background
For patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we collected the prospective data reported since 2010 to analyze the emerging chemotherapy-based treatment...
Background
Tyrosine kinase inhibitors (TKIs) contribute to the treatment of patients with anaplastic thyroid cancer (ATC). Although prospective clinical studies of TKIs exhibit limited efficacy, whether ATC patients benefit from TKI treatment in real-world clinical practice may enlighten future explorations. Therefore, we conducted this effective a...
Immunotherapy has revolutionized the treatment of hepatocellular carcinoma (HCC). However, whether adding immunotherapy to antiangiogenic therapy benefits patients with unresectable HCC (uHCC) more in the first-line setting remains controversial.
In this analysis, we compared the clinical outcomes of lenvatinib monotherapy with atezolizumab plus be...
Background:
Novel-fosfamides (NFOs) belong to active metabolites of ifosfamide that bypass the generation of toxic byproducts. In this analysis, we aimed to comprehensively assess the benefits and risks of NFO monotherapy or in combination with doxorubicin (DOX) versus single-drug DOX in previously untreated patients with advanced soft-tissue sarc...
Background:
Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets the human trophoblast cell-surface antigen 2 to deliver SN-38 to cancer cells. In this study, we assessed the efficacy and safety of SG in patients with relapsed or refractory metastatic triple-negative breast cancer (RM-TNBC).
Methods:
For this integrated analysis...
Background
Adebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, aimed to compare the survival data of adebrelimab (CAPSTONE-1 trial) with durvalumab (CASPIAN trial)...
Background
The prognosis of patients with relapsed Ewing sarcoma is poor. In this study, we aimed to pooled-analyze the efficacy and safety of the combination of irinotecan and temozolomide in treating patients with relapsed Ewing sarcoma.
Methods
PubMed, Cochrane CENTRAL, Web of Science, and EMBASE were systematically searched on September 27, 20...
Background:
Non-small-cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutant occurs in 3% of NSCLCs. Targeted agents for this population remain an unmet need. In this analysis, we pooled-analyzed the efficacy and safety of poziotinib, a novel tyrosine kinase inhibitor, in HER2 exon 20 mutant NSCLC.
Metho...
Background:
Taxane chemotherapy represents the standard of care in the second-line setting for non-small cell lung cancer (NSCLC) patients, but immunotherapy agents pose great challenges. Whether immunotherapy/chemotherapy alone or combination therapy has more benefits remains controversial. In this study, we provided comparisons to integrate the...
Background:
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy is the standard of care in treating advanced non-small cell lung cancer (NSCLC). Nevertheless, whether adding pemetrexed-based chemotherapy to EGFR-TKI targeted therapy furtherly prolongs survival outcomes and improves responses remains controversial. T...
Background:
Immunotherapy has revolutionized the treatment of advanced lung cancer. Nevertheless, it remains unclear whether adding stereotactic body radiotherapy (SBRT) to immunotherapy (IT) further improves responses and survival outcomes. Therefore, in this pooled analysis, we comprehensively compared IT plus SBRT with IT alone in patients with...
Background:
Ubiquitin-like with PHD and ring-finger domain 1 (UHRF1) has been defined as an oncogene in tumor cells. However, the role of UHRF1 in mediating metastasis in thyroid cancer remains unexplored. In this study, we aimed to investigate the metastatic function and the potential mechanisms of UHRF1 in thyroid cancer.
Methods:
Transwell as...
Background
Adding induction chemotherapy to concurrent platinum-based chemoradiotherapy has significantly prolonged the survival time of patients with locoregionally advanced nasopharyngeal carcinoma. In this study, we intend to evaluate the survival outcomes, responses, and incidences of toxicities of induction chemotherapy and the differences bet...
Background:
Cemiplimab has been widely recommended by international guidelines to treat patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). In this study, we conducted a comparative analysis to integrate the efficacy and safety data in the published prospective and retrospective studies for better understanding t...
Background
The major aim of this Bayesian network analysis was to determine the optimal treatment strategy for locoregionally advanced nasopharyngeal carcinoma (LANPC).
Method
We systematically searched databases and extracted data from randomized clinical trials involving LANPC patients randomly assigned to receive induction chemotherapy followed...
Purpose
As an antipsychotic agent that targets multiple neurotransmitter receptors, olanzapine has been added to antiemetic therapies. For better understanding the application of olanzapine in antiemetic strategies for breast cancer patients who suffered anthracycline plus cyclophosphamide-induced nausea and vomiting, we comprehensively reviewed th...
Background
Doxorubicin/Adriamycin (ADM) alone or combined with ifosfamide (IFO) (AI) is available for previously untreated advanced soft tissue sarcoma (ASTS). However, the clinical choice between them remains controversial. In this pooled analysis, we comprehensively compared the efficacy and tolerability of AI versus ADM in patients with ASTS.
M...
Purpose: As an antipsychotic agent that targets multiple neurotransmitter receptors, olanzapine has been added to antiemetic therapies. However, olanzapine is rarely used in the real-world antiemetic strategies for breast cancer patients who suffered chemotherapy-induced nausea and vomiting. Therefore, in this study, we comprehensively reviewed the...
Background:
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been demonstrated to improve the anti-cancer effects in combination with radiotherapy. However, the tolerability and safety of adding GM-CSF to radiotherapy in thoracic cancer patients need to be further explored.
Methods:
Between June 2020 and Sep 2020, seven patients wit...
Background:
Adjuvant trastuzumab improves survival outcomes of human epidermal receptor 2 positive early breast cancer patients. Currently, administration of 12 months adjuvant trastuzumab is the standard therapy. However, whether 6 months treatment is non-inferior to the standard 12 months treatment remains controversial.
Methods:
Relevant reco...
[This corrects the article DOI: 10.1155/2020/2368164.].
Background. The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive extensive-stage SCLC patients, the efficacy of immunotherapy in combination with cytotoxic chemothera...
Background:
The combination of durvalumab and tremelimumab results in clinical benefit, with a tolerable safety profile in patients with solid tumors.
Objective:
To evaluate the efficacy and safety of durvalumab in combination with tremelimumab compared with either drug alone.
Methods:
The online databases (PubMed, Web of Science, EMBASE, and...
Background:
Immune checkpoint inhibition has been increasingly used in breast cancer therapy. Understanding the benefit and risk of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is critical for clinical practice. This study aims to determine the objective response, disease control and adverse events of breast...
Background:
Gemcitabine combined the oral fluoropyrimidine capecitabine (GemCap) is an active antitumor therapy in the treatment of advanced or metastatic pancreatic cancer, and has been shown potential synergistic activity in previous clinical trials. In this study, we sought to systematically review and synthesize the efficacy and safety of GemC...
Background:
Induction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT) has been recommended as the first-line therapy for locoregional nasopharyngeal carcinoma (NPC). Due to the different chemotherapeutic drugs used in the IC and CCRT, the results remain controversial.
Methods:
PubMed, EMBASE, Web of Science, and Cochrane Libr...
Objectives
There is currently no effective salvage therapeutic modality that improves the survival outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma. However, the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors may provide clinical benefit for these advanced patients.
Materials and methods
The data...
Background: Tumor-draining lymph nodes (TDLN) played an important role in initiating immune responses. However, the immune status of TDLN in hepatocellular carcinoma (HCC) had not been well studied. Methods: We extracted the immune cells from the TDLN and peripheral blood mononuclear cell (PBMC) of 16 HCC patients. Using flow cytometry, we investig...
Cytokine-induced killer (CIK) cell therapy has recently been used as an adjuvant setting following resection of hepatocellular carcinoma (HCC), while its benefit remains unclear. This study aimed to evaluate the efficacy of adjuvant CIK application in solitary HCC patients undergoing curative resection with stratification of microvascular invasion...
The clinical significance of microRNAs (miRNAs) in intrahepatic cholangiocarcinoma (ICC) is unclear. The objective of this study is to examine the miRNA expression profiles and identify a miRNA signature for the prognosis of ICC.
Using a custom microarray containing 1,094 probes, the miRNA expression profiles of 63 human ICCs and nine normal intrah...
Anaplastic thyroid cancer (ATC), an undifferentiated subtype of thyroid cancer, is one of the most malignant endocrine cancer with low survival rate, and resistant to chemotherapy and radiation therapy. Here we found that UHRF1 was highly expressed in human ATC compared with normal tissue and papillary thyroid cancer (PTC). Knockdown of UHRF1 inhib...
There are few studies about origins of regulatory T (Treg) cells increased in primary hepatocellular carcinoma (HCC) tissue. Studies showed that Treg cells could be induced by transforming growth factor-beta1 (TGF-beta1), but the relation between TGF-beta1 expression and Treg cell infiltration is unclear in HCC tissue. This study was to investigate...
Citations
... Therefore, researchers have sought therapy that could inhibit tyrosine kinase activity in EGFR. Tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC) lung cancer patients significantly has a better response rate (RR), progression-free survival (PFS) and lower toxicity than chemotherapy [1]. Gefitinib and erlotinib are EGFR-TKI with side effects including skin rash, diarrhea, and nterstitial lung diseases (ILD). ...
... Induction (or neoadjuvant) chemotherapy (ICT) is currently a therapeutic standard for locally advanced nonmetastatic nasopharyngeal carcinomas (NPC) with a high level of evidence (1)(2)(3). Several randomized controlled trials, two meta-analyses (4,5) and two systematic reviews of literature (6,7) confirmed the positive impact of adding ICT to concurrent chemoradiation in locally advanced nonmetastatic NPC on different survival parameters. Nonendemic NPC is usually treated following the guidelines for endemic NPC although there are no specific trials for the former and the evidence for ICT is less clear (8)(9)(10)(11). ...
... Finally, like advanced basal cell carcinomas, advanced cutaneous squamous cell carcinomas may have high mutational burdens, a feature that correlates with response to immunotherapy. The anti-PD1 agent cemiplimab is active in advanced cutaneous squamous cell cancers and is FDA approved for this indication [79,93,94]. ...
... Initial therapy for localized Ewing sarcoma involves five chemotherapeutic agents administered in an alternating pattern, including doxorubicin and etoposide. In the context of recurrence, irinotecan (which is metabolized to the topoisomerase I inhibitor, SN-38) and temozolomide (TMZ) have been shown to be temporarily effective for a large fraction of patients 21 , and this combination has been used together with experimental agents 22,23 . Because of the relevance of these compounds for up-front and relapse therapy, we studied SN-38 (irinotecan for in vivo studies as a pro-drug), TMZ, etoposide, and doxorubicin in this investigation. ...
... The subsequent intergroup 0099 randomized trial confirmed that CCRT was better than radiotherapy alone for patients with locally advanced nasopharyngeal [16]. Several meta-analyses have already shown that CCRT combined with or without AC could significantly improve OS [17][18][19][20]. Thus, CCRT has become the core therapy for patients with locally advanced nasopharyngeal cancer (LA-NPC). ...
... The anthracycline doxorubicin is one of the most widely used chemotherapeutic agents for the treatment of many cancers and is used as a first-line treatment alone or in combination in different tumor types, including soft tissue sarcomas (STS) [1][2][3][4]. The potential of doxorubicin is strongly limited by its adverse events, particularly, but not only, cardiotoxicity that limits the overall cumulative dose of the drug [5,6]. ...
... The reported complete response (CR; no vomiting/ retching and no rescue medication) rate during the 0-120 h period in HEC is 34%-55% for the three antiemetic combinations (neurokinin-1 receptor antagonist [NK 1 RA], 5-hydroxytryptamine type-3 receptor antagonist [5-HT 3 RA], and dexamethasone) [8][9][10] and 50%-64% for the four antiemetic combinations (NK 1 RA, 5-HT 3 RA, dexamethasone, and olanzapine). 9,10 However, as there are individual differences in the degree of symptoms, it is necessary to select an appropriate antiemetic therapy that takes this into consideration. ...
... The decision regarding the optimal duration of adjuvant HER2 therapy remains controversial, and de-escalating HER2-targeted treatment has yet to become common practice [17,18]. The REaCT-HER TIME pilot study (NCT04928261) randomized patients with HER2+ early-stage breast cancer who had had upfront systemic treatment with no residual disease on surgical specimens to either six or twelve months of adjuvant HER2 treatment. ...
... In contrast to NSCLC, no predictive biomarkers to ICI response (or resistance) in SCLC have been validated and approved. However, several studies confirmed a substantial therapeutic benefit of adding ICIs to conventional chemotherapy as a first-line treatment for extensive SCLC [69,70]. Facchinett et al. summarized the results of four randomized trials involving >1500 patients with SCLC treated with combined ICI/chemotherapy vs. chemotherapy alone (platinumetoposide). ...
... Indeed, ICIs could improve the therapeutic effect by reversing the inhibitory immune microenvironment and enhancing the anti-tumor response. Combining the anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab demonstrated a higher rate of disease control than monotherapy in HNSCC patients [239]. Interestingly, the efficacy of durvalumab plus tremelimumab was also tested in metastatic/recurrent HNSCC patients and was associated with higher survival and response rates at 12 to 24 months [240,241]. ...
Reference: Immune checkpoints Head and Neck
